Everyone’s favorite bracket challenge has returned. That’s right—it’s time once again for Fierce Pharma Marketing’s annual ...
Novartis' two-drug regimen of Tafinlar and Mekinist has been approved by the FDA as the first therapy for solid tumours that have a BRAF V600E mutation – regardless of where they occur in the body.
This update to the popular V600 sports a new black design and adds video capture and menu themes. Other key features include quad-band GSM, Bluetooth, VGA camera, changeable metal casing, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results